Excess weight hikes risk of health double-whammy among older women
July 8 (UPI) -- Older women carrying excess weight have a higher risk of a life-threatening double-whammy, a new study says.
Women past menopause with a higher body mass index were more likely to develop breast cancer if they had heart disease, researchers reported Monday in the journal Cancer. BMI is an estimate of body fat based on height and weight.
Women with heart disease had a 31% increased risk of breast cancer for every 5-point increase in their BMI, results show.
By comparison, women without heart problems had a 13% increased risk for every 5-point BMI increase, results show.
"This suggests that among postmenopausal women with cardiovascular disease, prevention of obesity may lead to a greater reduction in breast cancer incidence compared to the general population," concluded the research team led by Heinz Freisling, a scientist of nutrition and metabolism with the International Agency for Research on Cancer.
For the study, researchers pooled data from two large-scale European health studies - the ongoing UK Biobank research project and the European Prospective Investigation Into Cancer and Nutrition.
They wound up with data on nearly 169,000 postmenopausal women, including almost 6,800 who developed breast cancer after an average follow-up of nearly 11 years.
Researchers estimate that the combination of excess weight and heart disease could cause an additional 153 cases of breast cancer per 100,000.
On the other hand, developing type 2 diabetes did not seem to affect women's breast cancer risk, researchers found.
"Emerging experimental research suggests that certain types of cardiovascular disease -- such as myocardial infarction [heart attack] -- can accelerate breast cancer growth by reprogramming of the innate immune system," researchers wrote.
Proteins secreted after heart failure have been shown to promote tumor formation and accelerate cancer growth, researchers said.
"The findings of this study could be used to inform risk-stratified breast cancer screening programs," Freisling said. "This study should also inspire future research to include women with a history of cardiovascular diseases in weight loss trials for breast cancer prevention."
More information
Harvard Medical School has more on heart disease and breast cancer.
Copyright © 2025 HealthDay. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic
CAMBRIDGE, United Kingdom and MONTREAL, July 10, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and the expansion of its research team. These developments represent a significant milestone in the company's ongoing progress in advancing its RNA-based immunotherapies, known as CryptiVax™, into clinical trials. Siri Brinchmann-Hansen Torhaug, Head of Oncology Development, and Gertrud Koefoed Rasmussen, Head of Development Operations, will both join Epitopea's Executive leadership team. They report into Dr. Klaus Edvardsen, who has served as Epitopea's Chief Medical Officer (CMO) since February 2025 and oversees the strategic direction of clinical trials and regulatory affairs. Epitopea's research team in Cambridge has been extended to include translational immunology capabilities with the appointment of Dr. Theres Oakes as Director of Translational Sciences and Dr. Lisa Smith as Director of Research (UK). Both report into Dr. Jon Moore, Co-founder and Chief Scientific Officer (CSO) of Epitopea, and will work in close collaboration with the clinical team to ensure the seamless integration of research and clinical strategies. Siri Brinchmann-Hansen Torhaug is a highly accomplished, board-certified, oncology specialist with extensive experience in clinical strategy and development. Siri has worked in various senior leadership roles, including as Chief Medical Officer at Nykode Therapeutics, where she was instrumental in developing clinical strategies for oncology and autoimmune disease therapies. She brings a wealth of experience from working across both early-phase translational research and late-stage clinical trials. At Epitopea, Siri will focus on clinical strategy and development, ensuring that the company's pipeline moves forward with precision and efficacy. 'It's a pleasure to join Epitopea's Executive and clinical leadership team,' said Siri Brinchmann-Hansen Torhaug, Head of Oncology Development. 'With my background in oncology clinical trials, I am excited to contribute to the company's innovative work in cancer immunotherapy. I look forward to working alongside Klaus and Gertrud to advance Epitopea's promising pipeline, with the aim of improving patient outcomes in oncology.' Gertrud Koefoed Rasmussen brings over 20 years of experience in clinical operations across multiple therapeutic areas, including oncology and rare diseases. Most recently, Gertrud held the position of VP and Head of Development Operations at Nykode Therapeutics, where she built and expanded the clinical operations department and led clinical trials across all phases of development. She has extensive experience in vendor management, regulatory compliance, and process optimization. At Epitopea, Gertrud will lead clinical trial management and regulatory compliance, ensuring that trials are conducted efficiently and in accordance with regulatory guidelines. 'Joining Epitopea is an exciting opportunity to leverage my expertise in clinical operations and contribute to the development of innovative therapies,' said Gertrud Koefoed Rasmussen, Head of Development Operations. 'I look forward to collaborating with the team to manage and execute clinical trials that will bring groundbreaking cancer immunotherapies to patients with significant unmet medical needs.' Dr. Klaus Edvardsen, CMO of Epitopea, commented, 'It is an honor to lead the formation of this clinical team, and I am thrilled to work with Gertrud and Siri, who both bring invaluable experience and expertise to Epitopea. Their leadership will be crucial as we move forward with our clinical trials and work to bring our transformative cancer immunotherapies to the clinic.' As part of the research team appointments, Dr. Theres Oakes brings extensive expertise in antigen-directed immuno-oncology through her academic training and prior role at Achilles Therapeutics. Dr. Lisa Smith brings considerable experience in drug discovery and oncology from her previous roles at Kudos Therapeutics, Mission Therapeutics and Benevolent AI. Dr. Jon Moore, CSO and Co-Founder of Epitopea, commented, 'We are harnessing the talents of our existing research team and recent joiners to build world-class cancer immunotherapeutics. To this end, we welcome Lisa to accelerate these efforts. Furthermore, with the translational sciences team we are building around Theres, we will have the capability to assess the performance of our immunotherapeutics in patients with unrivalled precision. It has been a real privilege to be able to build such a strong biology group, and I am very excited to see what impact we can make on the treatment of these devastating diseases.' About EpitopeaEpitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumor-specific antigens, which are known as Cryptigen™ TSAs, that are broadly shared across multiple patients with the same tumor type. The company has created an extensive library of novel Cryptigen™ TSAs, discovered by its proprietary CryptoMap™ platform that leverages immunopeptidomics, genomics, and a bioinformatics pipeline, allowing the identification of aberrantly-expressed, tumor-specific antigens (aeTSAs) that are hidden within cancer's 'junk' DNA. These hidden Cryptigen™ TSAs were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Université de Montréal. Epitopea is backed by leading life science investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarité FTQ, Investissement Québec, adMare BioInnovations, Jonathan Milner, the Harrington Discovery Institute, IRICoR and Novateur Ventures. The company has a license and research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA). Epitopea was founded in 2021 and consists of sister companies based in Cambridge, UK and in Montreal, Canada. For additional information, please visit and follow us on LinkedIn. For further information EpitopeaDr. Alan C. Rigby – Scius Communications (for Epitopea)Katja Stout+44 7789 435990katja@ Daniel Gooch+44 7747 875479daniel@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 hours ago
- Business Wire
Future Scientists From Europe Shine in Global Cambridge Schools Science Competition
CAMBRIDGE, England--(BUSINESS WIRE)--Three student teams from schools across Europe have won awards in the 2025 Cambridge Science Competition, run by the International Education group at Cambridge University Press & Assessment (Cambridge). The winning teams are from Türkiye, Ukraine, and Czech Republic and were selected by an expert panel of judges at the University of Cambridge for the high calibre of their projects, each of which aim to tackle real-world sustainability issues. Record numbers of students from Cambridge international schools across Europe are applying scientific thinking to address real-world challenges. Share The global Cambridge Science Competition, an extracurricular program for students aged 14–16, fosters a passion for innovation, research and critical thinking while honing practical lab skills. Participants are challenged to design projects with real-world relevance to their schools or communities, focusing on sustainability. This year, the competition saw record entries from student teams who are studying for Cambridge IGCSE science qualifications, taught across 6,000 schools globally. Best in Europe winner – Türkiye Students from Beştepe College in Türkiye took the top European prize for a pioneering investigation into the use of pinecone-derived probiotics to improve bean crop yields. By creating biodegradable probiotic beads, the team demonstrated a remarkable 105% increase in bean plant growth over 20 days. Their research could suggest a sustainable, low-cost alternative to chemical fertilizers. Ilgın Yıldırım Usta, IGCSE Biology Teacher, said: 'This project was more than just science—it became a chance for us to connect with something bigger: our responsibility to the environment and the future of agriculture.' Student, Ece Aydın, added: 'This experience has inspired me to keep asking questions, stay curious, and continue working on solutions that can help both people and the planet.' Team photo available here. Country Award - Ukraine A team of students from Gymnasium A+ school in Ukraine earned a Country Award for developing biodegradable bioplastics from brown seaweed. Their eco-friendly material offers a flexible, rapidly decomposing alternative to single-use plastics, addressing a pressing environmental issue. Student, Amina Sorochynska said: 'Winning a prize in this competition feels amazing. We're passionate about environmental issues and wanted to find a biodegradable alternative to plastic. It's great to know that our idea was thought to be potentially so useful.' Team photo available here. Country Award - Czech Republic Students from Townshend International School in the Czech Republic also received a Country Award for their study of moss species' ability to absorb water and filter pollutants. Their project showed how mosses could be used to combat drought and improve water quality, offering a natural bio-filtration and conservation solution. Student Abigail said: 'After winning, I feel much more confident in my abilities to problem-solve and design solutions. This experience has motivated me to take on more science projects in the future.' Team photo available here. Christine Ozden, Global Director for Climate Education at Cambridge, said: 'These students are a shining example of what's possible when young minds are given the opportunity to explore science in creative, meaningful ways. These three outstanding projects show how Cambridge students across Europe are using science to address real-world challenges. What unites them is not only great scientific thinking and application, but a deep sense of responsibility toward shaping a better future.' For more information about the competition, visit Cambridge Science Competition winners 2025.
UPI
6 hours ago
- UPI
Treasury Secretary Sean Duffy named interim NASA administrator
U.S. Department of Transportation Sean Duffy testifies at a House Appropriations subcommittee on May 14. He was also named interim administrator of NASA. File photo by Annabelle Gordon/UPI .. | License Photo July 10 (UPI) -- President Donald Trump on Monday named Transportation Secretary Sean Duffy to also serve as interim NASA administrator. Janet Petro, a former leader of the Kennedy Space Center, has been the agency's acting administrator since Trump became president on Jan. 20. The administrator reports directly to the president. "Sean is doing a TREMENDOUS job in handling our Country's Transportation Affairs, including creating a state-of-the-art Air Traffic Control systems, while at the same time rebuilding our roads and bridges, making them efficient, and beautiful, again," the president wrote in a post on Truth Social on Wednesday. "He will be a fantastic leader of the ever more important Space Agency, even if only for a short period of time. Congratulations, and thank you, Sean." Duffy, a lawyer and broadcaster who served in the U.S. House of Representatives from 2002 to 2010, has no science background. "Honored to accept this mission," Duffy posted on X. "Time to take over space. Let's launch." The president hasn't nominated anyone for the agency after he withdrew billionaire Jared Isaacman's name to lead NASA, citing a "thorough review of prior associations." The nomination was withdrawn on May 31, before the Senate was expected to vote on the nomination of Isaacman, who has twice traveled to space on private missions. It was withdrawn on the day SpaceX chief Elon Musk left the White House after leading the Department of Government Efficiency. Trump, in a post on Truth Social on Sunday, said it was "inappropriate that a very close friend of Elon, who was in the Space Business, run NASA, when NASA is such a big part of Elon's corporate life." In the message, Trump said he was "saddened to watch Elon Musk go completely 'off the rails,' essentially becoming a TRAIN WRECK over the past five weeks." The proposed 2026 fiscal year budget for NASA is $18.8 billion, which is a 25% reduction on overall funding and the smallest since 1961 when Alan Shepard became the first American in space. There are 17,000 permanent civil service employees with headquarters in Washington. Major locations are the Kennedy Space Center in Florida, the Johnson Space Center in Texas, the Jet Propulsion Laboratory in California, the Langley Research Center in Virginia, the Marshall Space Flight Center in Alabama and the Goddard Space Flight Center in Maryland. NASA relies on SpaceX to send its astronauts to the International Space Center. The agency also primarily uses private contractors and suppliers to build its rockets and related systems. The Department of Transportation has 57,000 employees, including the Federal Aviation Administration, safety of commercial motor vehicles and truckers, public transportation, railroads and maritime transport and ports. Several other political appointees are serving in multiple roles, according to NBC News. Secretary of State Marco Rubio currently serves as the interim national security adviser and national archivist. Deputy Attorney General Todd Blanche is the acting head of the Library of Congress. Jamieson Greer is the U.S. trade representative, acting director of the U.S. Office of Government Ethics and acting special counsel of the U.S. Office of Special Counsel. Russell Vought is director of the U.S. Office of Management and Budget and acting director of the Consumer Financial Protection Bureau. Richard Grenell, a special is president the Kennedy Center for the Performing Arts. And Daniel Driscoll is secretary of the Army and the acting director of the Bureau of Alcohol, Tobacco, Firearms and Explosives.
